GDC-1261 and INR731 enter phase 1, but how do they act?
ApexOnco Front Page
Recent articles
The group is pitting its anti-CD19 T-cell engager MK-1045 head-to-head against Blincyto.
Decisions and readouts loom for the SERDs Astra’s camizestrant and Roche’s giredestrant.
But biomarker enrichment and toxicity remain key for FX-909.
The first fruit of a long-standing deal with Roche enters phase 1 in March.
An FDA verdict is due in the third quarter, as Protagonist looks likely to opt out.
The month saw the first commissioner's priority voucher approval in oncology.
Welireg looks headed to regulators in second-line and adjuvant kidney cancer.
